Mercer Global Advisors
BMRN icon

Mercer Global Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Mercer Global Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.14M Sell
72,363
-18,109
-20% -$992K 0.01% 968
2026
Q1 		$5.11M Buy
90,472
+26,403
+41% +$1.54M 0.01% 752
2025
Q4 		$3.81M Buy
64,069
+910
+1% +$49.5K 0.01% 818
2025
Q3 		$3.42M Buy
63,159
+29,624
+88% +$1.69M 0.01% 804
2025
Q2 		$1.84M Buy
33,535
+3,791
+13% +$223K ﹤0.01% 920
2025
Q1 		$2.1M Buy
29,744
+11,641
+64% +$783K ﹤0.01% 827
2024
Q4 		$1.19M Buy
18,103
+9,915
+121% +$664K ﹤0.01% 1024
2024
Q3 		$574K Sell
8,188
-3,980
-33% -$333K ﹤0.01% 1263
2024
Q2 		$1.01M Sell
12,168
-104
-0.8% -$8.66K ﹤0.01% 960
2024
Q1 		$1.07M Sell
12,272
-263
-2% -$23.5K ﹤0.01% 935
2023
Q4 		$1.21M Sell
12,535
-180
-1% -$15.9K ﹤0.01% 901
2023
Q3 		$1.13M Sell
12,715
-2,839
-18% -$253K ﹤0.01% 898
2023
Q2 		$1.35M Sell
15,554
-60
-0.4% -$5.65K 0.01% 843
2023
Q1 		$1.52M Sell
15,614
-679
-4% -$70.4K 0.01% 762
2022
Q4 		$1.69M Sell
16,293
-1,594
-9% -$150K 0.01% 724
2022
Q3 		$1.52M Sell
17,887
-1,486
-8% -$132K 0.01% 708
2022
Q2 		$1.6M Buy
19,373
+16
+0.1% +$1.27K 0.01% 668
2022
Q1 		$1.49M Sell
19,357
-7
-0% -$586 0.01% 749
2021
Q4 		$1.71M Buy
19,364
+615
+3% +$50.7K 0.01% 678
2021
Q3 		$1.45M Sell
18,749
-5,375
-22% -$424K 0.01% 734
2021
Q2 		$2.01M Sell
24,124
-61
-0.3% -$4.84K 0.02% 567
2021
Q1 		$1.83M Sell
24,185
-2,380
-9% -$194K 0.02% 551
2020
Q4 		$2.33M Buy
26,565
+314
+1% +$24.9K 0.03% 390
2020
Q3 		$2M Buy
26,251
+23,384
+816% +$2.37M 0.03% 382
2020
Q2 		$354K Buy
2,867
+34
+1% +$3.38K 0.01% 796
2020
Q1 		$239K Buy
2,833
+14
+0.5% +$1.21K 0.01% 887
2019
Q4 		$238K Buy
+2,819
New +$213K ﹤0.01% 1008
2019
Q3 		– Sell
-2,725
Closed -$233K – 1134
2019
Q2 		$233K Buy
2,725
+84
+3% +$7.19K 0.01% 982
2019
Q1 		$235K Buy
+2,641
New +$245K 0.01% 928

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Mercer Global Advisors's BMRN Position: Q2 2026 in Review

Mercer Global Advisors reduced its BioMarin Pharmaceuticals (BMRN) stake by 20% in Q2 2026, selling an estimated $992K and leaving 72,363 shares worth $4.14M. The position accounts for 0.01% of the portfolio, ranked #968.

Mercer Global Advisors first reported a position in BMRN in Q1 2019 and has held it in 29 quarters since. The position peaked at $5.11M in Q1 2026. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Mercer Global Advisors held 72,363 shares of BioMarin Pharmaceuticals worth $4.14M as of Q2 2026.
  • Mercer Global Advisors sold 18,109 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $992K.
  • BioMarin Pharmaceuticals made up 0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #968 holding.
  • Mercer Global Advisors first reported a position in BioMarin Pharmaceuticals in Q1 2019 and has held it in 29 quarters since.
  • Mercer Global Advisors's BioMarin Pharmaceuticals position peaked at $5.11M in Q1 2026.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.